User login
Enter your username and password here in order to log in on the website:
Keywords
- ABPA_Aspergillus
- accompanying diseases
- air-improving devices
- allergy
- animals_pets
- antibiotic therapy
- asthma
- complementary medicine
- covid-19
- diabetes
- diagnostics
- drugs side effects
- drugs under development_genetic therapy
- ENT
- general aspects
- genetics
- health care
- hepatobiliary disease
- hygiene
- i.v.-lines
- inhalation
- lung
- microbiology
- miscellaneous
- modulator therapy
- MRSA
- nutrition and GI problems
- oxygen supplementation_therapy
- physiotherapy
- Pseudomonas aeruginosa
- psychosocial
- public facilities
- recreational activities
- reproduction
- research
- social law
- sport
- swine flu_novel influenza
- transplantation
- travelling
- vaccination
- ventilation
Topics
- Meveol®
- Hello I have just read: « A new treatment against cystic fibrosis could emerge by 2016. This is a project supported by Bpifrance (bank financing and investment) who just released € 10 million for a new medical program called Alipex. Of the three companies involved in research: Alaxia, a ...
- 15.04.2014
- Living in Athens with CF Recommended ?
- I have an 11 year old daughter with CF and we live in Abu Dhabi, UAE, but we may come to live in Athens, I am worried about the air pollution, we will be living in the hills outside Athens. Also Gala has just started to take Ivacaftor as she has the G551 mutation, is this going to be available ...
- 24.03.2014
- Kalydeco® off-label
- Dear expert team, my son has the following CFTR mutations: 1717-1G>A (class 1) und die mutation S549R (gating/connection, class 2 oder 3) Kaleydeco ® has indeed at the moment only market authorization for the class 3 mutation G551D. However, tests with other mutations have been done. There it ...
- 12.02.2014
- MIGLUSTAT
- Hello Do you have any news regarding research about MIGLUSTAT? Thank you.
- 03.02.2014
- Therapy of the protein
- Hello, We have learned in September by the "INSERM" (french national institute for health and medical research), about the discovery of 2 molecules acting on deltaF508 CFTR protein. What is the difference between theses 2 molecules and Vertex’s molecules (Ivacaftor® and Lumacaftor®) that are ...
- 08.01.2014
- POTENTIATOR / GALAPAGOS
- Hello An article published on 12/16/13 indicates that the biotechnology company Galapagos has a new drug candidate (potentiator) which will be tested in clinical trials. How much credit can you give to this notification? Have you more information? Thanks
- 08.01.2014
- Delta F 508
- Thank you in advance for giving us the latest positive or negative but true results on combined VX 770 and VX 809 clinical trials for example as we read everything and its opposite. It would be good to have regular news because for us, sick or close to sick people with CF, it is the little light ...
- 01.01.2014
- CF cure
- Where do we start to cure CF?
- 23.12.2013
- 508 r117h T5
- My grandson has recently been diagnosed with CF. His details are 508 and r117h T5. Sweat test 47. What CF symptoms will develop? Also - what medication will be available in the near future which may address the symptoms? Thank You
- 02.12.2013
- State of research?
- Dear expert team, How far advanced is the current state of research on VX809 really? Is there a chance for this drug to be released to the market this year (2013)? And is it correct that it is only applicable to the Delta F508 homozygous mutation – and only to patients in very bad ...
- 04.11.2013